Gilead sciences, inc.
GILD 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分較低，不過公司股利評分優異，若想穩定收息，仍可以考慮持續持有。但若僅以價值投資為目標可以減碼換股操作
GILD 近期報酬表現
1.17%
Gilead sciences, inc.
0.29%
同產業平均
1.03%
S&P500
與 GILD 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
AMGN | Amgen inc | 3 分 | 4 分 | 4 分 | 3 分 | 5 分 | |
BMY | Bristol-myers squibb company | 1 分 | 1 分 | 1 分 | 2 分 | 5 分 | |
NVS | Novartis ag | 2 分 | 3 分 | 5 分 | 2 分 | 5 分 | |
JNJ | Johnson & johnson | 3 分 | 1 分 | 4 分 | 3 分 | 5 分 | |
PFE | Pfizer inc | 3 分 | 3 分 | 4 分 | 2 分 | 5 分 |
- AMGN Amgen inc價值 3 分趨勢 4 分波段 4 分籌碼 3 分股利 5 分查看更多
GILD 公司資訊
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada, Truvada for PrEP, Tybost, Veklury, Vemlidy, Viread, Vosevi, Yescarta and Zydelig. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, and Domvanalimab and zimberelimab, and seladelpar. Seladelpar shall be used for the treatment of primary biliary cholangitis (PBC), including pruritus. The Company operates in more than 35 countries.